Alpha1-proteinase inhibitor(Grifols SA)

Massachusetts-based genetic therapy biotech Airna has dosed the first patient in the RepAIR1 Phase I trial of AIR-001, a GalNAc-conjugated oligonucleotide designed to correct the PiZ mutation in SERPINA1 mRNA by recruiting endogenous ADAR enzymes. The firm simultaneously announced that the FDA has granted Orphan Drug Designation to AIR-001 for alpha-1 antitrypsin deficiency (AATD). The open-label study, registered as NCT07431112, is enrolling adults with the PiZZ genotype across sites in Australia and the United Kingdom, with planned expansion to approximately 20 sites in 11 countries and a target enrolment of 54 patients. Primary endpoints cover safety, pharmacokinetics, and pharmacodynamic changes across total alpha-1 antitrypsin (AAT), functional AAT, Z-AAT, and M-AAT. AATD is caused by mutations in SERPINA1, with the PiZ variant driving the most common and severe form of the disease. The resulting Z-AAT protein misfolds and accumulates in hepatocytes, causing progressive liver injury, while reduced circulating functional AAT leaves lung tissue vulnerable to protease-mediated destruction. The dual organ involvement is a defining feature of AATD biology and a persistent challenge for therapeutic development. Research context The mechanistic logic behind AIR-001 maps directly onto the molecular basis of PiZZ (homozygous PiZ mutation) disease. The PiZ mutation is a single nucleotide substitution — a G-to-A change at the DNA level that produces a glutamate-to-lysine substitution in the AAT protein, driving its misfolding and polymerisation. ADAR enzymes catalyse adenosine-to-inosine editing of RNA, which ribosomes read as guanosine, making the PiZ site a tractable target for A-to-I correction without altering genomic sequence. AIR-001 exploits this by deploying a GalNAc-conjugated guide oligonucleotide to recruit endogenous ADAR to the relevant position on SERPINA1 mRNA. GalNAc conjugation provides hepatocyte-selective uptake via the asialoglycoprotein receptor, concentrating the drug in the liver where AAT is produced. If editing is efficient enough to restore meaningful M-AAT output, the approach could simultaneously reduce pathological Z-AAT accumulation and raise circulating functional AAT — addressing both disease compartments with a single subcutaneous agent. AIRNA’s platform was founded on research by Thorsten Stafforst at the University of Tübingen and Jin Billy Li at Stanford, whose work established the feasibility of recruiting native ADAR for therapeutic RNA correction. The reversibility of RNA editing is a design feature with practical implications. Because SERPINA1 mRNA is continuously transcribed, editing must be maintained through repeat dosing — but this also means the intervention can be stopped, a consideration relevant to safety monitoring in early-phase trials and to future combination strategies. Standard of care and where current therapies fall short The only approved disease-specific therapy for AATD remains intravenous plasma-derived AAT augmentation, first approved in 1987 and available in the US through products including Prolastin-C (Grifols), Aralast NP and Glassia (Takeda), and Zemaira (CSL Behring). Weekly IV infusions partially compensate for low circulating AAT in the lung but do not address the toxic gain-of-function from Z-AAT accumulation in the liver. No pharmacological therapy for AATD-associated liver disease has been approved. For patients with end-stage organ involvement, transplantation remains the only definitive option. The dependence on human plasma supply, the burden of weekly infusions, and the absence of any liver-directed therapy define the gaps that newer modalities are attempting to fill. AIR-001’s subcutaneous route and its theoretical capacity to act on both lung and liver disease position it differently from augmentation therapy, though whether preclinical signals translate to meaningful clinical benefit in both compartments remains to be established in RepAIR1 and subsequent trials. Competitive landscape The most clinically advanced novel agent in AATD is fazirsiran (ARO-AAT), an RNAi therapeutic developed by Arrowhead Pharmaceuticals in partnership with Takeda. Fazirsiran uses siRNA to suppress SERPINA1 expression in hepatocytes, reducing Z-AAT production and liver accumulation. It completed Phase II evaluation in the SEQUOIA trial, where it demonstrated reductions in hepatic Z-AAT and improvements in liver enzyme levels, and holds FDA Breakthrough Therapy Designation for AATD-associated liver disease. An NDA submission is anticipated, which would make fazirsiran the first approved pharmacological treatment for AATD liver disease. The mechanistic distinction between fazirsiran and AIR-001 is significant: fazirsiran suppresses all SERPINA1 expression indiscriminately, reducing Z-AAT but not restoring M-AAT, whereas AIR-001 aims to convert Z-AAT mRNA into M-AAT mRNA, theoretically producing functional protein rather than simply reducing a toxic one. Whether that distinction produces a clinically meaningful difference in lung outcomes — where circulating AAT levels matter — is one of the central questions AIR-001’s development will need to answer. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Grifols' Cairo project is part of a national initiative to achieve self-sufficiency in plasma-derived medicines. Grifols & Orange Business Complete landmark phase of Data Centre for Plasma Derivatives Facility, designed to boost healthcare in Egypt Global healthcare company Grifols is working with French telecoms giant Orange to create a sustainable supply of essential therapeutics for life-threatening diseases in Egypt. Orange Business –  the enterprise division of telecoms company, Orange Group – has completed the initial stage of a new data centre and communications infrastructure in Cairo, for Grifols Egypt for Plasma Derivatives (GEPD). GEPD is a joint venture between Grifols and Egypt's National Service Projects Organisation (NSPO), which manufactures military and civilian products and provides contracting services. The project is part of a national initiative to achieve self-sufficiency in plasma-derived medicines -- vital treatments extracted from blood plasma for various serious medical conditions. Partnership to boost Egyptian healthcare Grifols, a specialist in plasma-derived medicines, is seeking to interconnect critical healthcare facilities, including a plasma laboratory, co-location data centre, plasma warehouse, 20 plasma donation centres, and a state-of-the-art manufacturing facility. Orange Business is providing co-location services, which allows GEPD to house its servers in Orange's data centre. The company is also supplying communication services and support with equipment procurement. The networked healthcare infrastructure is designed to ensure efficient operations and “the timely delivery of plasma-derived medicines to patients in need”, said Dr Ahmed Serag, Chief Strategy and Projects Officer at GEPD. Kristof Symons, CEO International at Orange Business, said: "Our technical skills, experienced resources, and global knowledge were pivotal in enabling Grifols to replicate its global business model in Egypt. This project shows how Orange Business can support its customers in creating a positive impact in today's society." About Grifols Multinational healthcare company Grifols was founded in 1940 in Barcelona, Spain employs 24,000 people worldwide, and specialises in the production of plasma-derived medicines and the development of diagnostic solutions. Its core activities include plasma collection, the manufacture of protein therapies derived from plasma, and fractionation, a process that separates a mixture into two or more fractions with different chemical and physical properties. Grifols is conducting clinical trials for its Alzheimer's treatment , a plasma-based therapy aimed at slowing cognitive decline in patients with mild to moderate Alzheimer's disease. The company is also researching treatments for liver diseases and immunodeficiencies. Among Grifols' products are Gamunex, an immune globulin therapy used to treat primary immunodeficiency, and Prolastin, used in the treatment of alpha-1 antitrypsin deficiency. The firm also produces albumin solutions for fluid replacement and coagulation factors for haemophilia treatment. In the diagnostic sector, Grifols offers blood typing systems and infectious disease screening tools. The company operates a network of plasma donation centres, primarily in the US, which form a crucial part of its supply chain for plasma-derived therapies.